A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral Sclerosis
Latest Information Update: 30 Jun 2021
At a glance
- Drugs BIIB 100 (Primary) ; Edaravone; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Biogen
Most Recent Events
- 25 Jun 2021 Status changed from recruiting to completed.
- 19 Mar 2021 Planned End Date changed from 31 Mar 2021 to 14 Jun 2021.
- 19 Mar 2021 Planned primary completion date changed from 31 Mar 2021 to 14 Jun 2021.